REFERENCES
- Brady KT, Grice DE, Dustan L, Randall C. Gender differences in substance use disorders. Am J Psychiatry 1993; 150(11):1707–1711.
- López A, Becoña E. Depression and cocaine dependence. Psychol Rep 2007; 100(2):520–524.
- Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 48(1):43–51.
- Conner KR, Pinquart M, Holbrook AP. Meta-analysis of depression and substance use and impairment among cocaine users. Drug Alcohol Depend 2008; 98(1–2):13–23.
- Poling J, Kosten TR, Sofuoglu M. Treatment outcome predictors for cocaine dependence. Am J Drug Alcohol Abuse 2007; 33(2):191–206.
- McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, Petkova E. Desipramine treatment of cocaine-dependent patients with depression: A placebo-controlled trial. Drug Alcohol Depend 2005; 80(2):209–221.
- Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001; 63(3):207–214.
- Ciraulo DA, Knapp C, Rotrosen J, Sarid-Segal O, Ciraulo AM, LoCastro J, Greenblatt DJ, Leiderman D. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 2005; 100(Suppl. 1):23–31.
- Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7(3):249–264.
- Kent JM. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet 2000; 355(9207):911–918.
- Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: Differential modulation of cell surface expression and signal transduction. Mol Pharmacol 2008; 73(3):748–757.
- Yoon SJ, Pae CU, Kim DJ, Namkoong K, Lee E, Oh DY, Lee YS, Shin DH, Jeong YC, Kim JH, Choi SB, Hwang IB, Shin YC, Cho SN, Lee HK, Lee CT. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(7):1196–1201.
- Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(1):55–60.
- Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: A placebo-controlled pilot study. Int Clin Psychopharmacol 2005; 20(5):253–256.
- McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008; 35(3):334–342.
- Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, Shand D. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008; 27(3):326–333.
- Zueco Pereez PL. Mirtazapine in the treatment of cocaine-dependence in patients with methadone. Actas Esp Psiquiatr 2002; 30(6):337–342.
- McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL, O’Brien CP. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis 1985; 173(7):412–423.
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
- Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1):50–55.
- Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34(1):19–28.
- Guy W, ed. Clinical Global Impression (CGI) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976.
- Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2):193–213.
- Winokur A, DeMartinis NA, 3rd, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64(10):1224–1229.
- Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study. Biol Psychiatry 2000; 48(1):75–78.